Erratum: Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. (Cancer 2014 120 (1780-1786))

S. Pant; L. K. Martin; S. Geyer; L. Wei; K. Van Loon; N. Sommovilla; M. Zalupski; R. Iyer; D. Fogelman; A. H. Ko; T. Bekaii-Saab

doi:10.1002/cncr.29197

Erratum: Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. (Cancer 2014 120 (1780-1786))

S. Pant
, L. K. Martin
, S. Geyer
, L. Wei
, K. Van Loon
, N. Sommovilla
, M. Zalupski
, R. Iyer
, D. Fogelman
, A. H. Ko
, T. Bekaii-Saab

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	1154
Number of pages	1
Journal	Cancer
Volume	121
Issue number	7
DOIs	https://doi.org/10.1002/cncr.29197
State	Published - Apr 1 2015

Access to Document

10.1002/cncr.29197

Cite this

Pant, S., Martin, L. K., Geyer, S., Wei, L., Van Loon, K., Sommovilla, N., Zalupski, M., Iyer, R., Fogelman, D., Ko, A. H., & Bekaii-Saab, T. (2015). Erratum: Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. (Cancer 2014 120 (1780-1786)). Cancer, 121(7), 1154. https://doi.org/10.1002/cncr.29197

@article{e112a31a511b42d6beccb3c201ef7170,

title = "Erratum: Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. (Cancer 2014 120 (1780-1786))",

author = "S. Pant and Martin, \{L. K.\} and S. Geyer and L. Wei and \{Van Loon\}, K. and N. Sommovilla and M. Zalupski and R. Iyer and D. Fogelman and Ko, \{A. H.\} and T. Bekaii-Saab",

year = "2015",

month = apr,

day = "1",

doi = "10.1002/cncr.29197",

language = "English",

volume = "121",

pages = "1154",

journal = "Cancer",

issn = "0008-543X",

number = "7",

}

Pant, S, Martin, LK, Geyer, S, Wei, L, Van Loon, K, Sommovilla, N, Zalupski, M, Iyer, R, Fogelman, D, Ko, AH & Bekaii-Saab, T 2015, 'Erratum: Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. (Cancer 2014 120 (1780-1786))', Cancer, vol. 121, no. 7, pp. 1154. https://doi.org/10.1002/cncr.29197

Erratum: Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. (Cancer 2014 120 (1780-1786)). / Pant, S.; Martin, L. K.; Geyer, S. et al.
In: Cancer, Vol. 121, No. 7, 01.04.2015, p. 1154.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Erratum

T2 - Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. (Cancer 2014 120 (1780-1786))

AU - Pant, S.

AU - Martin, L. K.

AU - Geyer, S.

AU - Wei, L.

AU - Van Loon, K.

AU - Sommovilla, N.

AU - Zalupski, M.

AU - Iyer, R.

AU - Fogelman, D.

AU - Ko, A. H.

AU - Bekaii-Saab, T.

PY - 2015/4/1

Y1 - 2015/4/1

UR - https://www.scopus.com/pages/publications/84925356006

U2 - 10.1002/cncr.29197

DO - 10.1002/cncr.29197

M3 - Comment/debate

AN - SCOPUS:84925356006

SN - 0008-543X

VL - 121

SP - 1154

JO - Cancer

JF - Cancer

IS - 7

ER -

Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N et al. Erratum: Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. (Cancer 2014 120 (1780-1786)). Cancer. 2015 Apr 1;121(7):1154. doi: 10.1002/cncr.29197

Erratum: Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. (Cancer 2014 120 (1780-1786))

Access to Document

Other files and links

Cite this